Litigation Details for Hospira Inc. v. Amneal Pharmaceuticals LLC (D. Del. 2015)

Hospira Inc. v. Amneal Pharmaceuticals LLC (D. Del. 2015)

Docket		Date Filed	2015-08-11
Court	District Court, D. Delaware	Date Terminated
Cause	35:145 Patent Infringement	Assigned To	Richard Gibson Andrews
Jury Demand	None	Referred To
Patents	8,242,158; 8,338,470; 8,455,527; 8,648,106
Link to Docket	External link to docket

Details for Hospira Inc. v. Amneal Pharmaceuticals LLC (D. Del. 2015)

Date Filed	Document No.	Description	Snippet	Link To Document
2015-08-11	4		the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) US 8,242,158 B1; US 8,338,470 … 11 August 2015 1:15-cv-00697-RGA Patent None District Court, D. Delaware	External link to document
2015-08-11	57		multiple terms in U.S . . Patent Nos. 8,242, 158 ("the '158 patent"); 8,338,4 70 ("… construction of multiple terms in U.S. Patent Nos. 8,242,158, 8,338,470, 8,455,527, and 8,648,106 (see…quot;the '4 70 patent"); 8,455,527 ("the '527 patent"); and 8,648, 106 ("the…the '106 patent") (collectively "the patents-in-suit"). The Court has considered the…quot;It is a bedrock principle of patent law that the claims of a patent define the invention to which	External link to document

Hospira Inc. v. Amneal Pharmaceuticals LLC, 1:15-cv-00697-RGA: Litigation Summary and Patent Analysis

Last updated: August 2, 2026

Hospira’s Delaware case against Amneal challenged an ANDA for a generic dexmedetomidine hydrochloride injection, the active ingredient in Precedex. The dispute centered on Hospira patents covering ready-to-use dexmedetomidine formulations and related pharmaceutical compositions. The case was filed under the Hatch-Waxman framework after Amneal made a Paragraph IV certification against Hospira’s Orange Book-listed patents.

What drug and patents were involved in Hospira v. Amneal?

The case involved dexmedetomidine hydrochloride injection, an intensive-care sedative marketed by Hospira under the Precedex brand. Dexmedetomidine is an alpha-2 adrenergic receptor agonist used for sedation in mechanically ventilated and procedural patients.

The principal patents associated with the litigation were:

Patent	General subject matter	Relevant patent position
U.S. Patent No. 8,455,527	Ready-to-use dexmedetomidine formulations	Formulation and concentration claims
U.S. Patent No. 8,648,106	Dexmedetomidine pharmaceutical compositions	Low-concentration, stable injectable formulations

The patents were directed to commercial formulation characteristics rather than the basic dexmedetomidine molecule. The earlier compound and basic formulation patents had substantially earlier expiration dates, while the later Hospira patents created a potential barrier to generic ready-to-use products.

Hospira alleged that Amneal’s proposed ANDA product would infringe claims covering dexmedetomidine formulations with specified concentrations, solvents, pH conditions, and stability characteristics. Amneal disputed infringement and challenged the asserted claims on validity grounds.

When was the Hospira v. Amneal case filed?

Hospira filed the action in the U.S. District Court for the District of Delaware in 2015. The case was assigned to Judge Richard G. Andrews under civil action number 1:15-cv-00697-RGA.

The proceeding was an ANDA patent case. Amneal’s Paragraph IV certification gave Hospira a statutory basis to sue under 21 U.S.C. § 355(j)(5)(B)(iii), and the filing of the complaint triggered the Hatch-Waxman litigation framework.

The case involved the standard commercial issues for a generic injectable:

• Whether the ANDA formulation fell within the asserted patent claims.
• Whether the claims were valid over prior art.
• Whether the 30-month stay delayed FDA approval.
• Whether Amneal could launch before patent expiration.
• Whether the parties could resolve the case through a settlement or license.

What was the Orange Book status of the Hospira dexmedetomidine patents?

The asserted Hospira patents were associated with the Precedex injectable product and were listed in the FDA’s Orange Book as product or use-related patents for the relevant dosage forms. Orange Book listing allowed Hospira to bring a statutory infringement action after Amneal’s Paragraph IV certification.

Orange Book protection for dexmedetomidine did not have the same structure as biologic exclusivity. Precedex is a small-molecule injectable, so the relevant FDA framework was an ANDA, not a biosimilar application under the Public Health Service Act.

The commercial impact of an Orange Book patent depended on four factors:

1. The patent’s expiration date.
2. The scope of the claims relative to Amneal’s formulation.
3. Whether the patent survived validity challenges.
4. Whether the parties reached a licensed-entry settlement.

What were the main technical issues in the litigation?

Ready-to-use dexmedetomidine formulations

The central technical issue was whether Amneal’s proposed product used the formulation architecture claimed by Hospira. Ready-to-use injectable products have commercial advantages because they avoid dilution and reduce preparation steps in hospital settings.

Hospira’s patents focused on formulation features that could improve product stability and permit administration without hospital compounding. The relevant claim limitations included formulation concentration, aqueous composition, and stability requirements.

Concentration and formulation overlap

The litigation required comparison of Amneal’s ANDA formulation with the numerical and structural limitations in the asserted claims. In pharmaceutical patent cases, minor differences in concentration or excipient composition can determine infringement.

The analysis likely turned on:

• The amount of dexmedetomidine hydrochloride per unit volume.
• The presence and quantity of sodium chloride or other excipients.
• The pH range.
• Whether the product was supplied in a premixed, ready-to-use form.
• Whether the claimed stability characteristics were present in the ANDA product.
• Whether the claims required a specific formulation structure or only functional performance.

Claim construction

The District of Delaware conducted claim-construction proceedings addressing the meaning of technical formulation terms. Claim construction was important because the patent claims included quantitative and functional limitations. A narrow construction could exclude Amneal’s formulation; a broader construction could increase infringement exposure but create greater prior-art risk.

What validity defenses did Amneal raise?

Amneal’s principal defenses in this type of ANDA action were noninfringement, invalidity, and unenforceability. The relevant validity theories included:

Obviousness

Amneal could argue that a person skilled in pharmaceutical formulation would have been motivated to develop a stable, ready-to-use dexmedetomidine injection based on existing dexmedetomidine formulations, known injectable excipients, and routine stability testing.

Hospira’s counterargument was that the claimed formulation required more than routine optimization. It could rely on unexpected stability, concentration, or storage results to distinguish the claims from prior art.

Anticipation

An anticipation defense would require a single prior-art reference to disclose every limitation of an asserted claim. Because the Hospira patents were formulation patents, anticipation could depend on whether earlier references disclosed the same concentration, excipients, pH, and stability characteristics in combination.

Written description and enablement

Amneal could challenge whether the patent specification adequately supported the full scope of the formulation claims and enabled the claimed compositions without undue experimentation. These defenses are particularly relevant where claims cover broad numerical ranges or multiple formulation variants.

Double patenting

Hospira’s patent family included related formulation filings. Amneal could raise obviousness-type double-patenting arguments if the asserted claims were materially indistinct from claims in an earlier Hospira patent.

Did Amneal file a Paragraph IV challenge?

Yes. The case arose from an ANDA Paragraph IV certification. A Paragraph IV certification asserts that an Orange Book-listed patent is invalid, unenforceable, or would not be infringed by the proposed generic product.

The certification exposed Amneal to litigation but also preserved the possibility of an earlier generic launch. If the litigation had proceeded to a final judgment against Amneal, the launch date would have depended on the patent findings, any injunction, and the expiration of applicable regulatory exclusivity.

A Paragraph IV filing can also create 180-day generic exclusivity issues. That issue depends on whether the ANDA applicant was a first applicant and whether the statutory forfeiture provisions applied. The docket alone does not establish that Amneal held first-applicant status for this product.

What was the 30-month stay impact?

Hospira’s timely infringement action triggered the statutory 30-month stay of FDA approval, subject to court rulings and statutory exceptions. The stay generally prevents FDA approval of the ANDA during the initial litigation period unless the court enters a decision earlier or the stay is otherwise terminated.

For an injectable product, the stay can have material commercial value because hospital products often have concentrated supplier markets and high switching costs. A delayed approval can preserve brand or authorized-generic volume even where the active ingredient itself is no longer protected by a basic compound patent.

How strong was Hospira’s patent estate?

Hospira’s estate was stronger on formulation differentiation than on molecule exclusivity.

Strengths

• The patents covered commercial ready-to-use formulations rather than only a broad therapeutic concept.
• Formulation claims can be difficult to design around if the branded and generic products use similar concentration and stability specifications.
• Orange Book listing created a direct Hatch-Waxman enforcement pathway.
• Injectable formulation manufacturing and stability data can give the patent holder an evidentiary advantage when the ANDA contains confidential product information.

Weaknesses

• Numerical formulation claims are vulnerable to obviousness attacks based on routine optimization.
• Earlier dexmedetomidine formulations and injectable-product references could provide prior-art material.
• A generic applicant may design around concentration, excipient, container, or labeling limitations.
• The patents did not restore exclusivity for the dexmedetomidine molecule itself.

The estate therefore created a meaningful launch barrier but did not eliminate design-around risk. Its commercial value depended on whether the asserted claims captured the specific ANDA product rather than merely the broader concept of dexmedetomidine injection.

What formulation patents protected Precedex?

The formulation patents protected aspects of dexmedetomidine injection intended to provide a stable pharmaceutical product in a ready-to-use form. The relevant protections were distinct from method-of-use patents.

Formulation protection

Formulation claims generally covered:

• Dexmedetomidine hydrochloride in an aqueous carrier.
• Defined concentration ranges.
• Specified excipient systems.
• pH conditions.
• Stability characteristics.
• Premixed or ready-to-administer presentations.

Method-of-use protection

The case was principally a formulation dispute rather than a broad method-of-use case. Method-of-use patents can protect sedation regimens, patient populations, or administration protocols, but such claims raise separate issues under the Hatch-Waxman skinny-label framework.

If an ANDA applicant omits a patented indication from its labeling, the applicant may reduce method-of-use exposure while still infringing composition claims. Formulation patents are generally more difficult to avoid through label carving because they concern the product itself.

What manufacturing and intellectual-property barriers affected generic entry?

Generic injectable manufacturers face barriers beyond the patent claims.

Sterility and container-closure systems

A generic dexmedetomidine injection must satisfy FDA requirements for sterility, particulate control, container compatibility, extractables and leachables, and manufacturing-process validation. These requirements can increase the cost and timing of launch even after patent clearance.

Stability data

Hospira’s patents were tied to formulation stability. Amneal’s ANDA would have required stability data supporting the proposed shelf life and storage conditions. A formulation that avoids patent infringement may still require additional development work to meet FDA specifications.

Supply-chain qualification

Hospitals often require supplier qualification for injectable products. Contract manufacturing, active pharmaceutical ingredient supply, and container availability can delay a commercial launch after FDA approval.

Labeling

The generic’s labeling must be therapeutically equivalent to the reference product, subject to permissible omissions. If the asserted patents covered the formulation, label changes would have limited value as a design-around strategy.

Which companies were competing in dexmedetomidine?

The competitive field included:

• Hospira, the Precedex reference-product manufacturer.
• Amneal Pharmaceuticals, the ANDA litigant.
• Other generic injectable manufacturers pursuing dexmedetomidine products.
• Authorized or affiliated generic suppliers associated with the reference-product supply chain.
• Hospital-focused injectable companies such as Fresenius Kabi, Hikma, and other established generic manufacturers.

Competition in dexmedetomidine depended on whether products were supplied in concentrated vials, premixed bags, or other ready-to-use presentations. Premixed products can command a commercial advantage in hospital formularies because they reduce preparation and dosing errors.

What was the litigation status and commercial outcome?

The action was a Delaware Hatch-Waxman dispute over Amneal’s proposed dexmedetomidine product and Hospira’s formulation patents. The central legal questions were claim scope, infringement, validity, and the timing of FDA approval.

The docket and associated patent record should be read together with the FDA Orange Book and any later settlement or dismissal filings. A case dismissal alone would not establish whether Amneal obtained a license, whether the parties agreed to a confidential entry date, or whether Hospira prevailed on the merits. Commercial entry therefore depends on the final case disposition, any settlement terms, and the status of the asserted patents.

No biosimilar pathway was implicated. The product was a small-molecule injectable regulated through the ANDA process.

How does Hospira’s patent estate compare with molecule-level exclusivity?

Protection type	Commercial effect	Relevance to this case
Basic dexmedetomidine compound patent	Broad protection against products containing the molecule	Earlier protection; not the principal dispute
Formulation patent	Protects composition, concentration, excipients, or stability	Central to Hospira’s case
Method-of-use patent	Protects a labeled therapeutic use or dosing method	Secondary relevance
FDA new-drug exclusivity	Delays certain ANDA approvals	Separate from patent validity
Orange Book listing	Enables Hatch-Waxman litigation	Procedural basis for suit
Manufacturing know-how	Can delay design-around or commercial scale-up	Important for injectable entry

Formulation patents can extend commercial protection after compound-patent expiry, but they generally provide narrower protection. Their value is highest when the claimed formulation is the market standard and difficult to reproduce with a non-infringing alternative.

Key Takeaways

• Hospira v. Amneal, 1:15-cv-00697-RGA, was a Delaware Hatch-Waxman case involving generic dexmedetomidine hydrochloride injection.
• The dispute centered on Hospira formulation patents, including U.S. Patent Nos. 8,455,527 and 8,648,106.
• The patents protected ready-to-use and stable injectable formulations rather than the underlying dexmedetomidine molecule alone.
• Amneal’s Paragraph IV certification triggered patent litigation and the statutory FDA approval stay.
• The principal issues were formulation claim construction, infringement, obviousness, anticipation, and the scope of the ANDA product.
• Formulation patents created a meaningful but narrower barrier than molecule-level patents.
• Biosimilar law was not relevant because dexmedetomidine is a small-molecule drug.
• Generic launch timing depended on the final litigation disposition, any settlement terms, FDA approval, and the remaining life of the asserted patents.

FAQs About Hospira v. Amneal

What product did Amneal seek to market?

Amneal sought FDA approval for a generic dexmedetomidine hydrochloride injection corresponding to Hospira’s Precedex product.

Were the Hospira patents compound patents?

No. The principal patents at issue were formulation patents directed to ready-to-use, stable dexmedetomidine injectable compositions.

Could Amneal avoid infringement by changing its label?

A label change would have had limited value against composition claims because formulation patents generally cover the product supplied, not only the labeled indication.

Was this a biosimilar case?

No. The case involved an ANDA for a small-molecule injectable and proceeded under the Hatch-Waxman Act.

What was the main generic-entry risk?

The main risk was that Amneal’s formulation would be found to fall within Hospira’s Orange Book-listed claims, delaying FDA approval or requiring a license, settlement, or non-infringing product redesign.

References

1. U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations. Orange Book.

2. U.S. Food and Drug Administration. (n.d.). Abbreviated new drug application process. FDA.

3. U.S. Patent and Trademark Office. (2013). U.S. Patent No. 8,455,527: Dexmedetomidine pre-mixed formulation. Washington, DC.

4. U.S. Patent and Trademark Office. (2014). U.S. Patent No. 8,648,106: Dexmedetomidine pharmaceutical compositions. Washington, DC.

5. Hospira, Inc. v. Amneal Pharmaceuticals, LLC, No. 1:15-cv-00697-RGA, U.S. District Court for the District of Delaware.